Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP8 | Q14790 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141577 | 0.90 | CASP8 (0.49) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL1247127 | 0.86 | LDHA (0.49) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL2143075 | 0.86 | CASP8 (0.47) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL996815 | 0.85 | LDHA (0.51) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL24362835 | 0.83 | CASP8 (0.45) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL3551574 | 0.82 | CASP8 (0.47) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL491211 | 0.82 | HPGDS (0.46) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL13368828 | 0.81 | CASP8 (0.41) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL3556297 | 0.81 | CASP8 (0.43) | CASP8L3MBTL1LDHAALDH1A1KDM4E | |
| SCHEMBL10253093 | 0.80 | CASP8 (0.42) | CASP8L3MBTL1LDHAALDH1A1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CASP8 1889/4885L3MBTL1 3267/4885LDHA 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.